What is Boundless Bio, Inc. Common Stock (BOLD) stock price today?

Boundless Bio, Inc. Common Stock (BOLD) currently trades at $1.46 per share. The stock has a market capitalization of $33.61M and a P/E ratio of —x.

Is BOLD stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Boundless Bio, Inc. Common Stock has a Smart Value Score of 30/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is -1.89.

Is Boundless Bio, Inc. Common Stock financially healthy?

Boundless Bio, Inc. Common Stock's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of -1.89 places it in the distress.

BOLD

Boundless Bio, Inc. Common Stock

NASDAQ: BOLD · HEALTHCARE · BIOTECHNOLOGY

$1.46

+0.69% today

Updated 2026-04-30

Market cap

$33.61M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.60

Dividend yield

—

52W range

$1 – $2

Volume

0.2M

Market cap

$33.61M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.60

Dividend yield

—

52W range

$1 – $2

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-1.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$4.00

+173.97%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy0 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.50x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -1.89 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-10.53M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-45.90M	$-49.43M	$-65.36M	$-58.20M	$-12.88M
EPS	—	—	—	—	$-2.60
Free cash flow	$-40.66M	$-47.49M	$-63.38M	$-47.21M	$-10.53M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
BOLD	$33.61M	30	4.3	3.0	5.0	5.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Boundless Bio, Inc. Common Stock trades at $1.46. Our Smart Value Score of 30/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -1.89, it sits in the distress.

Frequently asked questions

What is Boundless Bio, Inc. Common Stock's stock price?

Boundless Bio, Inc. Common Stock (BOLD) trades at $1.46.

Is Boundless Bio, Inc. Common Stock overvalued?

Smart Value Score 30/100 (Grade F, Strong Sell).

What is the price target of Boundless Bio, Inc. Common Stock (BOLD)?

The analyst target price is $4.00, representing +174.0% upside from the current price of $1.46.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

-1.89 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

boundlessbio.com

Quick metrics

P/S ratio—

ROE-46.70%

Beta-0.26

50D MA$1.22

200D MA$1.21

Shares out0.02B

Float0.02B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

BOLD vs LLY →BOLD vs JNJ →BOLD vs ABBV →Stock screener →